WHY BIG PHARMA IS DEAD IN THE WATER—GET READY TO STEP-UP TO THE PLATE
THE WHY
Between 1985 and 1995, Big Pharma sold off its facilities and skilled people that created its products.
When less products came through, it engaged in horizontal M&A activity that cost $BNs but didn’t help—in fact, things got more complex, and most failed.
Then, Big Pharma focussed on rare disease, orphan indications and all things cancer—the volumes were so small, that to impress investors, it had to charge unaffordable, eye-watering prices.
They tried $1M per treatment with Glybera, a gene therapy; went belly up.
Gene therapies, when hospital costs are taken into account on top of the price tag, aren’t flying, even though it has spent $BNs buying small companies making them—another fat failure.
In desperation, some of them turned to gene therapy for the world’s population, commonly known as SARS-CoV-2 injections.
The only way to do that in the timeframe was to commit criminal fraud.
We know all about that now…
THE WHAT
If you believe the above (I’ve been studying and communicating t…